<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334214</url>
  </required_header>
  <id_info>
    <org_study_id>484137-CS2</org_study_id>
    <nct_id>NCT03334214</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (IONIS-DGAT2Rx, an Antisense Inhibitor of Diacylglycerol Acyltransferase 2) Administered Once-Weekly for 13 Weeks in Adult Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the Safety, Tolerability, and Pharmacodynamics effect of IONIS
      DGAT2Rx in up to 45 Adult Patients with Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This short-term study will assess changes in hepatic steatosis over a 13-week treatment
      period in a patient population with higher risk for development of Nonalcoholic fatty liver
      disease (NAFLD) and Nonalcoholic steatohepatitis (NASH), obese type 2 diabetes mellitus
      (T2DM) with elevated HbA1c.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events that are related to treatment with IONIS DGAT2Rx</measure>
    <time_frame>Up to 176 days</time_frame>
    <description>The safety and tolerability of IONIS DGAT2Rx will be assessed by determining the incidence and severity of adverse events that are related to treatment with IONIS DGAT2Rx</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in liver fat percentage</measure>
    <time_frame>Week 15</time_frame>
    <description>Absolute change in liver fat percentage as quantified by MRI-PDFF from Baseline to Post-Treatment MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative percent change in liver fat percentage</measure>
    <time_frame>Week 15</time_frame>
    <description>Relative percent change in liver fat percentage from Baseline to Post-Treatment MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 30% relative reduction in liver fat percentage</measure>
    <time_frame>Week 15</time_frame>
    <description>Proportion of subjects with ≥ 30% relative reduction in liver fat percentage from Baseline to Post-Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in plasma lipoprotein profile</measure>
    <time_frame>Week 14</time_frame>
    <description>Percent change in plasma lipoprotein profile (triglycerides, total cholesterol, LDL-C, apolipoprotein B (apoB), very low density lipoproteins (VLDL), HDL, and Non-HDL) from Baseline to the average of the Post-Treatment values assessed 1 and 2 weeks after the last dose (Post-Treatment 1 and Post-Treatment 2 Visits)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in parameters of IR</measure>
    <time_frame>Week 14</time_frame>
    <description>Percent change in parameters of IR (FPG, insulin, and homeostatic model assessment - insulin resistance (HOMA-IR)) from Baseline to Post-Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HbA1C</measure>
    <time_frame>Week 14</time_frame>
    <description>Absolute change in HbA1C from Baseline to Post-Treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hepatic Steatosis</condition>
  <arm_group>
    <arm_group_label>IONIS DGAT2Rx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sterile saline 0.9)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS DGAT2Rx</intervention_name>
    <description>Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks</description>
    <arm_group_label>IONIS DGAT2Rx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline 0.9%</description>
    <arm_group_label>Placebo (sterile saline 0.9)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have given written informed consent and be able to comply with all study
             requirements.

          -  Males or females aged 18-75, inclusive, at the time of Informed Consent.

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or post-
             menopausal.

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method.

          -  BMI ≥ 27.0 - ≤ 39.0 kg/m².

          -  Diagnosis of Type 2 Diabetes Mellitus with an HbA1c ≥7.3% and ≤9.5% at screening.

          -  Must have been on a stable dose of Oral Antidiabetic Therapy for a minimum of 3 months
             prior to Screening.

          -  ≥ 10% liver fat prior to randomization assessed by MRI-PDFF.

          -  Stable body weight for at least 3 months before screening.

        Exclusion Criteria:

          -  Clinically-significant abnormalities in medical history or physical examination.

          -  Clinically-significant abnormalities in screening laboratory values that would render
             a subject unsuitable for inclusion, per Sponsor.

          -  Evidence of uncorrected hypothyroidism or hyperthyroidism results at Screening.

          -  History of solid organ transplantation or renal dialysis.

          -  Clinically-significant complications of diabetes.

          -  Treatment with another Study Drug, biological agent, or device within one-month of
             screening.

          -  Known history or evidence of liver disease with a positive test for HIV, Hepatitis C
             virus (HCV), or chronic Hepatitis B virus (HBV), or chronic liver disease other than
             NASH.

          -  Recent history of, or current drug or alcohol abuse.

          -  Current use of concomitant medications known to significantly impact body weight or
             that may cause liver toxicity, per Investigator

          -  Use of anticoagulant/Antiplatelet agents unless the dose has been stable for 4 weeks
             prior to the first dose of study drug]

          -  Use of non-steroidal anti-inflammatory drug nimesulide or any other drug influencing
             coagulation (except lose-dose aspirin).

          -  Use of obeticholic acid or ursodeoxycholic acid

          -  Considered unsuitable for inclusion by the Principal Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Bhanot</last_name>
    <role>Study Director</role>
    <affiliation>Ionis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>1-800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-863</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Chełm</city>
        <zip>22-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Mysłowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Wierzchosławice</city>
        <zip>33-122</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Łódź</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ionis Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Steatosis</keyword>
  <keyword>IONIS-DGAT2Rx</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

